NCT01132235View on ClinicalTrials.gov

An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use

PHASE4UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Psoriasis
Interventions
BIOLOGICAL

etanercept

50mgs subcutaneous injections twice a week for 12 weeks

Trial Locations (1)

33136

RECRUITING

Florida Academic Dermatology Center, Miami

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Florida Academic Dermatology Centers

OTHER